Effectiveness of entecavir in preventing hepatocellular carcinoma development is genotype-dependent in hepatitis B virus-associated liver cirrhosis

Table 1 Difference in the impact of entecavir treatment on the risk of hepatocellular carcinoma in patients with hepatitis B virus-associated cirrhosis in various regions of the world

Ref.	Region	Main genotype	Prevalence ratio	Entecavir administered to HBV cirrhotics patients	Observation period (yr)	Incidence of HCC (%/yr)
Riveiro-Barciela et al[3]	Spain (Caucasian)	D	2%-7%	64	4.6	1.0
Coffin et al[4]	Canada (South)	D	< 2%	25	3.2	1.3
Hosaka et al[21]	Japan (Tokyo)	C	< 2%	79	5.0	1.4
Papatheodoridis et al[14]	Greece	A	2%-7%	69	3.3	1.8
Idilman et al[11]	Turkey	D	2%-7%	72	4.0	2.2
Arends et al[13]	Caucasus	D	> 8%	155	3.5	2.2
Su et al[8]	Taiwan	C	> 8%	1315	4.0	2.4
Köklü et al[12]	Turkey	D	2%-7%	73	3.0	2.7
Wong et al[1]	Hong Kong	C	> 8%	482	5.0	2.8
Watanabe et al[10]	Japan (Ehime)	C	2%-7%	86	5.0	2.9
Chen et al[9]	Taiwan	C	> 8%	586	4.9	3.1
Chen et al[2]	China (Chinese)	C	> 8%	61	4.0	3.3
Kim et al[5]	Korea	C	2%-7%	367	5.0	3.6
Choi et al[6]	Korea	C	2%-7%	510	4.0	3.8

HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus.